KLRS NASDAQ
Kalaris Therapeutics Inc
1W: -7.5%
1M: -30.8%
3M: -41.9%
YTD: -67.5%
1Y: -55.5%
$2.70
-0.15 (-5.26%)
Weekly Expected Move ±5.8%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-09-13
Earliest Filing
2025-03-18
Latest Filing
target: 2
partner: 2
acquirer: 1
Counterparties (Filed by KLRS)
5 relationshipsCompanies named in KLRS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AlloVir, Inc. | ALVR | acquirer | Acquired Kalaris Therapeutics, Inc. in a merger transaction consummated on March 18, 2025. | 2025-03-18 | View |
| Kalaris Therapeutics, Inc. | KLRS | target | Target company in the merger with AlloVir, Inc., formerly known as Kalaris Tx, Inc. | 2025-03-18 | View |
| Kalaris Therapeutics, Inc. | KLRS | target | Target company in the proposed merger with AlloVir, Inc. | 2024-11-08 | View |
| AMAG Pharmaceuticals, Inc. | AMGN | partner | Sublessee of laboratory and office space from AlloVir, Inc. | 2021-09-13 | View |
| BP Bay Colony LLC | — | partner | Landlord leasing additional laboratory and office space to AlloVir, Inc. | 2021-09-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-20 | Officer/Director Change; Exhibits | View | |
| 2026-07-17 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-06 | Officer/Director Change | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-04-10 | Officer/Director Change | View | |
| 2026-03-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-12-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-20 | Shareholder Nominations; Other Events | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-16 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-04-04 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-18 | Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; C | Acquisition | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR